Magnetic Resonance Molecular Imaging of Thrombosis in an Arachidonic Acid Mouse Model Using an Activated Platelet Targeted Probe

被引:39
作者
Klink, Ahmed [1 ,2 ]
Lancelot, Eric [3 ]
Ballet, Sebastien [3 ]
Vucic, Esad [1 ]
Fabre, Jean-Etienne [4 ]
Gonzalez, Walter [3 ]
Medina, Christelle [3 ]
Corot, Claire [3 ]
Mulder, Willem J. M. [1 ]
Mallat, Ziad [2 ]
Fayad, Zahi A. [1 ,5 ]
机构
[1] Mt Sinai Sch Med, Translat & Mol Imaging Inst, Imaging Sci Labs,Dept Radiol, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
[2] Hop Europeen Georges Pompidou, AP HP, INSERM, Paris Cardiovasc Res Ctr, Paris, France
[3] Guerbet, Roissy, France
[4] Univ Strasbourg, INSERM, U964, CNRS,UMR7104, Illkirch Graffenstaden, France
[5] Mt Sinai Sch Med, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA
关键词
arterial thrombosis; atherosclerosis; magnetic resonance imaging; platelets; thrombosis; CONTRAST AGENT; ATHEROSCLEROTIC PLAQUES; ARTERIAL THROMBOSIS; CORONARY-THROMBOSIS; FIBRINOGEN; BINDING; RECEPTOR; ATHEROTHROMBOSIS; ANTAGONISTS; INTEGRINS;
D O I
10.1161/ATVBAHA.109.198556
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Atherosclerotic plaque rupture leads to acute thrombus formation and may trigger serious clinical events such as myocardial infarction or stroke. Therefore, it would be valuable to identify atherothrombosis and vulnerable plaques before the onset of such clinical events. We sought to determine whether the noninvasive in vivo visualization of activated platelets was effective when using a target-specific MRI contrast agent to identify thrombi, hallmarks of vulnerable or high-risk atherosclerotic plaques. Methods and Results-Inflammatory thrombi were induced in mice via topical application of arachidonic acid on the carotid. Thrombus formation was imaged with intravital fluorescence microscopy and molecular MRI. To accomplish the latter, a paramagnetic contrast agent (P975) that targets the glycoprotein alpha(IIb)beta(3), expressed on activated platelets, was investigated. The specificity of P975 for activated platelets was studied in vitro. In vivo, high spatial-resolution MRI was performed at baseline and longitudinally over 2 hours after injecting P975 or a nonspecific agent. The contralateral carotid, a sham surgery group, and a competitive inhibition experiment served as controls. P975 showed a good affinity for activated platelets, with an IC50 (concentration of dose that produces 50% inhibition) value of 2.6 mu mol/L. In thrombosed animals, P975 produced an immediate and sustained increase in MRI signal, whereas none of the control groups revealed any significant increase in MRI signal 2 hours after injection. More important, the competitive inhibition experiment with an alpha(IIb)beta(3) antagonist suppressed the MRI signal enhancement, which is indicative for the specificity of P975 for the activated platelets. Conclusion-P975 allowed in vivo target-specific noninvasive MRI of activated platelets. (Arterioscler Thromb Vasc Biol. 2010;30:403-410.)
引用
收藏
页码:403 / U59
页数:9
相关论文
共 40 条
[1]   ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J].
Anderson, Jeffrey L. ;
Adams, Cynthia D. ;
Antman, Elliott M. ;
Bridges, Charles R. ;
Califf, Robert M. ;
Casey, Donald E., Jr. ;
Chavey, William E., II ;
Fesmire, Francis M. ;
Hochman, Judith S. ;
Levin, Thomas N. ;
Lincoff, A. Michael ;
Peterson, Eric D. ;
Theroux, Pierre ;
Wenger, Nanette Kass ;
Wright, R. Scott ;
Smith, Sidney C., Jr. ;
Jacobs, Alice K. ;
Adams, Cynthia D. ;
Riegel, Barbara .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :652-726
[2]   Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis [J].
Bates, SM ;
Lister-James, J ;
Julian, JA ;
Taillefer, R ;
Moyer, BR ;
Ginsberg, JS .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (04) :452-456
[3]   In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent [J].
Botnar, RM ;
Buecker, A ;
Wiethoff, AJ ;
Parsons, EC ;
Katoh, M ;
Katsimaglis, G ;
Weisskoff, RM ;
Lauffer, RB ;
Graham, PB ;
Gunther, RW ;
Manning, WJ ;
Spuentrup, E .
CIRCULATION, 2004, 110 (11) :1463-1466
[4]   Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes [J].
Briley-Saebo, Karen C. ;
Mulder, Willem J. M. ;
Mani, Venkatesh ;
Hyafil, Fabien ;
Amirbekian, Vardan ;
Aguinaldo, Juan Gilberto S. ;
Fisher, Edward A. ;
Fayad, Zahi A. .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 26 (03) :460-479
[5]   Molecular, cellular and functional imaging of atherothrombosis [J].
Choudhury, RP ;
Fuster, V ;
Fayad, ZA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) :913-925
[6]   Reproducibility of carotid atherosclerotic lesion type characterization using high resolution multicontrast weighted cardiovascular magnetic resonance [J].
Chu, Baocheng ;
Phan, Binh An P. ;
Balu, Niranjan ;
Yuan, Chun ;
Brown, B. Greg ;
Zhao, Xue-Qiao .
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2006, 8 (06) :793-799
[7]   99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism [J].
Dunzinger, Andreas ;
Hafner, Franz ;
Schaffler, Gottfried ;
Piswanger-Soelkner, Jutta-Claudia ;
Brodmann, Marianne ;
Lipp, Rainer W. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (11) :2082-2087
[8]   Atherothrombosis and high-risk plaque Part I: Evolving concepts [J].
Fuster, V ;
Moreno, PR ;
Fayad, ZA ;
Corti, R ;
Badimon, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :937-954
[9]   Platelets in inflammation and atherogenesis [J].
Gawaz, M ;
Langer, H ;
May, AE .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3378-3384
[10]   Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions [J].
Goto, S ;
Tamura, N ;
Ishida, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (02) :316-323